Drug profile · INN
butenafine hydrochloride
LOTRIMIN ULTRA
butenafine hydrochloride (LOTRIMIN ULTRA) is a squalene monooxygenase inhibitor. Route of administration: topical. Current US regulatory status: approved.
Drug details — butenafine hydrochloride
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
butenafine hydrochloride (LOTRIMIN ULTRA) is a squalene monooxygenase inhibitor. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Squalene monooxygenase inhibitor
Primary target: Squalene monooxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is butenafine hydrochloride?
butenafine hydrochloride (LOTRIMIN ULTRA) is a squalene monooxygenase inhibitor. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for butenafine hydrochloride?
LOTRIMIN ULTRA is a marketed brand name for butenafine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of butenafine hydrochloride?
butenafine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.